Search

Your search keyword '"Kawano, Y."' showing total 3,027 results
Start Over Author "Kawano, Y." Publication Type Academic Journals

Refine your results

3,027 results on '"Kawano, Y."'

2. Phase II Study of Nivolumab Plus Ipilimumab with Platinum-Based Chemotherapy for Treatment-Naïve Advanced Non-Small Cell Lung Cancer with Untreated Brain Metastases: NIke Trial (LOGiK2004)

Author

Tsuchiya-Kawano Y, Shiraishi Y, Kiyomi F, and Okamoto I

Subjects
clinical trial, nsclc, nivolumab plus ipilimumab, brain metastases, intracranial response rate, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Yuko Tsuchiya-Kawano,1 Yoshimasa Shiraishi,2 Fumiaki Kiyomi,3 Isamu Okamoto2 1Department of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kitakyushu, Japan; 2Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; 3Statistics and Data Center, Clinical Research Support Center Kyushu, Fukuoka, JapanCorrespondence: Isamu OkamotoResearch Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582, JapanTel +81-92-642-5378Fax +81-92-642-5390Email okamoto.isamu.290@m.kyushu-u.ac.jpAbstract: The standard of care for advanced non-small cell lung cancer (NSCLC) without known driver oncogenes is immune checkpoint inhibitor (ICI) therapy combined with platinum-based chemotherapy. About 20% of patients with advanced NSCLC have brain metastases, which are related to poor prognosis. However, the effect of ICI therapy combined with platinum-based chemotherapy on untreated brain metastases derived from NSCLC remains unclear. The primary endpoint of this study is intracranial response rate as determined by modified Response Evaluation Criteria in Solid Tumors (RECIST) for brain metastases of ≥ 5 mm as target lesions. Eligible patients are 20 years of age or older with chemotherapy-naïve advanced NSCLC and at least one brain metastasis ≥ 5 mm in size that has not been previously treated. Patients receive nivolumab plus ipilimumab intravenously combined with histology-based platinum doublet chemotherapy (two cycles). Individuals with known genetic driver alterations such as those affecting EGFR or ALK are excluded. Planned enrollment is 30 patients over 2.5 years at 27 oncology facilities in Japan. This is the first prospective study to focus on the intracranial response to ICI therapy combined with platinum-based chemotherapy in patients with untreated brain metastases derived from NSCLC. If the study demonstrates intracranial efficacy for this patient population, then this regimen has the potential to become a new treatment option for such individuals.Keywords: clinical trial, NSCLC, nivolumab plus ipilimumab, brain metastases, intracranial response rate

Published
2021

5. Tear volume estimation using a modified Schirmer test: a randomized, multicenter, double-blind trial comparing 3% diquafosol ophthalmic solution and artificial tears in dry eye patients

Author

Miyake H, Kawano Y, Tanaka H, Iwata A, Imanaka T, and Nakamura M

Subjects
Schirmer, diquafosol, tear, dry eye, multicenter, Ophthalmology, RE1-994
Abstract

Hideki Miyake,1 Yuri Kawano,2 Hiroshi Tanaka,2 Akihiro Iwata,3 Takahiro Imanaka,1 Masatsugu Nakamura1 1Ophthalmic Disease Area Strategy Department, 2Clinical Operations Department, 3Data Science Department, R&D Division, Santen Pharmaceutical Co., Ltd. Osaka, Japan Purpose: We aimed to evaluate the feasibility of using a modified Schirmer test to determine the increase in tear volume after administration of 3% diquafosol ophthalmic solution (diquafosol 3%) in dry eye patients. Patients and methods: A randomized, multicenter, prospective, double-blind clinical study recruited 50 qualified subjects. They received diquafosol 3% in one eye and artificial tears in the other eye. The study protocol comprised a screening and treatment procedure completed within 1 day. The Schirmer test was performed on closed eyes three times a day. The primary efficacy end points were the second Schirmer test scores 10 minutes after the single dose. Secondary end points were the third Schirmer test scores 3 hours and 40 minutes after the single dose and the symptom scores prior to the second and third Schirmer tests. Results: According to the Schirmer test, 10 minutes after administration, diquafosol 3% significantly increased tear volume compared to artificial tears. Diquafosol 3% and artificial tears both showed significant improvements in the symptom scores compared to baseline. However, there was no significant difference in the symptoms score between diquafosol 3% and artificial tears. Conclusion: The modified Schirmer test can detect a minute change in tear volume in dry eye patients. These findings will be useful in the diagnosis of dry eye, assessment of treatment benefits in daily clinical practice, and the development of possible tear-secreting compounds for dry eye. Keywords: P2Y2, efficacy, Diquas®

Published
2016

20. Evaluation of the ATCA fast controller standard for ITER diagnostics

Author

Simrock, S., Bertalot, L., Cheon, M., Hansalia, C., Joonekindt, D., Jablonski, G., Kawano, Y., Klotz, W.-D., Kondoh, T., Kozak, T., Makijarvi, P., Makowski, D., Napieralski, A., Orlikowski, M., Park, M., Petrov, S., Piotrowski, A., Predki, P., Semenov, I., Shelukhin, D., Udintsev, V., Vayakis, G., Wallander, A., Walsh, M., Wu, S., Yang, S.Q., and Yonekawa, I.

Published
2012
Full Text
View/download PDF

41. W -band transmitter and receiver for 10-Gb/s impulse radio with an optical-fiber interface

Author

Nakasha, Y., Sato, M., Tajima, T., Kawano, Y., Suzuki, T., Takahashi, T., Makiyama, K., Ohki, T., and Hara, N.

Subjects
Error-correcting codes -- Analysis, Fiber optics -- Usage, Transceivers -- Design and construction, Mobile communication systems -- Analysis, Wireless communication systems -- Analysis, Fiber optics, Transceiver, Wireless technology, Business, Computers, Electronics, Electronics and electrical industries
Published
2009

48. AC transport current loss characteristics of YBCO coated conductors subjected to bending strains

Author

Kataoka, A., Tsukamoto, O., Sekizawa, S., Saitoh, T., Kawano, Y., Iijima, Y., Kashima, N., and Nagaya, S.

Subjects
Alternating current -- Analysis, Electric power systems -- Electric losses, Electric power systems -- Analysis, Business, Electronics, Electronics and electrical industries
Abstract

The analysis describes the characteristics of the AC transport current loss of various YBCO coated conductors (CCs) that are subjected to tensile bending strains. The loss is found to be independent of the manufacture, as well as the directions of the bending strains in these conductors.

Published
2007

Catalog

Books, media, physical & digital resources
See catalog results